Michael Schmitz
Stock Analyst at Guggenheim
(2.71)
# 2,099
Out of 5,012 analysts
9
Total ratings
71.43%
Success rate
15.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Downgrades: Neutral | $109 → $97 | $94.38 | +2.78% | 3 | Sep 30, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $32.74 | +31.34% | 1 | Sep 24, 2025 | |
| EXEL Exelixis | Reiterates: Buy | $45 | $38.64 | +16.46% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $47.82 | +71.48% | 2 | Oct 28, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $9.75 | +310.26% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.51 | - | 1 | Jan 3, 2023 |
Merus
Sep 30, 2025
Downgrades: Neutral
Price Target: $109 → $97
Current: $94.38
Upside: +2.78%
Genmab
Sep 24, 2025
Upgrades: Buy
Price Target: $43
Current: $32.74
Upside: +31.34%
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $38.64
Upside: +16.46%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $47.82
Upside: +71.48%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $9.75
Upside: +310.26%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.51
Upside: -